Wanlong Ma

1.5k total citations
71 papers, 1.0k citations indexed

About

Wanlong Ma is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Wanlong Ma has authored 71 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Hematology, 27 papers in Molecular Biology and 27 papers in Genetics. Recurrent topics in Wanlong Ma's work include Cancer Genomics and Diagnostics (16 papers), Acute Myeloid Leukemia Research (16 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). Wanlong Ma is often cited by papers focused on Cancer Genomics and Diagnostics (16 papers), Acute Myeloid Leukemia Research (16 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers). Wanlong Ma collaborates with scholars based in United States, China and Denmark. Wanlong Ma's co-authors include Maher Albitar, Hagop M. Kantarjian, Ola Landgren, Neil E. Caporaso, Gerald E. Marti, Richard B. Hayes, Fatima Abbasi, Paolo Ghia, Francis J. Giles and Chen-Hsiung Yeh and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Wanlong Ma

68 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wanlong Ma United States 18 548 405 322 283 235 71 1.0k
Yvona Brychtová Czechia 19 704 1.3× 422 1.0× 221 0.7× 450 1.6× 294 1.3× 71 1.2k
Mirosław Majewski Poland 16 279 0.5× 522 1.3× 308 1.0× 353 1.2× 456 1.9× 28 1.4k
Iman Jilani United States 21 814 1.5× 578 1.4× 565 1.8× 557 2.0× 308 1.3× 54 1.6k
Kourong Miao China 17 342 0.6× 560 1.4× 202 0.6× 197 0.7× 260 1.1× 79 1.1k
Kimberly Hayes United States 19 753 1.4× 428 1.1× 833 2.6× 394 1.4× 337 1.4× 38 1.5k
Carsten Schwäenen Germany 19 319 0.6× 663 1.6× 151 0.5× 420 1.5× 377 1.6× 25 1.4k
Oscar Brück Finland 19 174 0.3× 285 0.7× 271 0.8× 217 0.8× 427 1.8× 44 1.1k
Shelonitda Rose United States 16 412 0.8× 750 1.9× 405 1.3× 433 1.5× 1.1k 4.6× 56 1.8k
Linda Wellik United States 20 306 0.6× 724 1.8× 471 1.5× 404 1.4× 444 1.9× 34 1.3k
Alicja Gruszka Italy 20 378 0.7× 395 1.0× 274 0.9× 380 1.3× 259 1.1× 36 945

Countries citing papers authored by Wanlong Ma

Since Specialization
Citations

This map shows the geographic impact of Wanlong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wanlong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wanlong Ma more than expected).

Fields of papers citing papers by Wanlong Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wanlong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wanlong Ma. The network helps show where Wanlong Ma may publish in the future.

Co-authorship network of co-authors of Wanlong Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Wanlong Ma. A scholar is included among the top collaborators of Wanlong Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wanlong Ma. Wanlong Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Albitar, Maher, Hong Zhang, Andrew Ip, et al.. (2023). Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors. Heliyon. 9(5). e16261–e16261. 14 indexed citations
3.
Ahn, Inhye E., Xin Tian, David Ipe, et al.. (2020). Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. Journal of Clinical Oncology. 39(6). 576–585. 56 indexed citations
4.
Ma, Wanlong, et al.. (2018). A Meta-analysis of the Value of vWF in the Diagnosis of Liver Cirrhosis with Portal Hypertension. Journal of Clinical and Translational Hepatology. 6(4). 1–6. 10 indexed citations
5.
Ma, Wanlong, et al.. (2017). IDH1 and IDH2 : Founding or Progressor Mutations in Myeloid Neoplasms. Blood. 130. 405–405. 2 indexed citations
6.
Albitar, Adam, Wanlong Ma, & Maher Albitar. (2017). Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations. Journal of Visualized Experiments. 4 indexed citations
7.
Ma, Wanlong, Steven G. Brodie, Sally Agersborg, Vincent Funari, & Maher Albitar. (2017). Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits. Molecular Diagnosis & Therapy. 21(5). 571–579. 17 indexed citations
8.
Ma, Wanlong, et al.. (2016). Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome. Genetic Testing and Molecular Biomarkers. 20(7). 341–345. 9 indexed citations
9.
Ma, Wanlong, et al.. (2015). Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer. Journal of Cancer. 6(5). 409–411. 7 indexed citations
10.
Ma, Wanlong, et al.. (2014). Diagnostic and Prognostic Scoring System for Prostate Cancer Using Urine and Plasma Biomarkers. Genetic Testing and Molecular Biomarkers. 18(3). 156–163. 17 indexed citations
11.
Ma, Wanlong, Xi Zhang, Xiuqiang Wang, et al.. (2011). MPL Mutation Profile in JAK2 Mutation-negative Patients With Myeloproliferative Disorders. Diagnostic Molecular Pathology. 20(1). 34–39. 29 indexed citations
12.
Lee, Tai‐Sung, et al.. (2011). Effects of Clinically Relevant MPL Mutations in the Transmembrane Domain Revealed at the Atomic Level through Computational Modeling. PLoS ONE. 6(8). e23396–e23396. 11 indexed citations
13.
Ma, Wanlong, Hagop M. Kantarjian, Ke Zhang, et al.. (2010). Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Medical Genetics. 11(1). 163–163. 15 indexed citations
14.
Ma, Wanlong, Hagop M. Kantarjian, Xi Zhang, et al.. (2010). JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms. PLoS ONE. 5(8). e12165–e12165. 15 indexed citations
15.
Zhang, Ke, Wanlong Ma, Hairong Li, et al.. (2010). Ubiquitin‐proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease. Journal of Gastroenterology and Hepatology. 26(4). 751–758. 13 indexed citations
16.
Ma, Wanlong, Hagop M. Kantarjian, Xi Zhang, et al.. (2010). Ubiquitin–proteasome system profiling in acute leukemias and its clinical relevance. Leukemia Research. 35(4). 526–533. 10 indexed citations
17.
Ma, Wanlong, Hagop M. Kantarjian, B. Nebiyou Bekele, et al.. (2009). Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome. Clinical Cancer Research. 15(11). 3820–3826. 40 indexed citations
18.
Albitar, Maher, Wanlong Ma, Hagop Kantarjian, & Francis J. Giles. (2009). Response:Plasma and JAK2 mutation. Blood. 114(1). 224–224. 7 indexed citations
19.
Ma, Wanlong, Hagop M. Kantarjian, Susan O’Brien, et al.. (2008). Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 112(6). 1306–1312. 28 indexed citations
20.
Ma, Wanlong, Hagop M. Kantarjian, Xi Zhang, et al.. (2008). Mutation Profile of JAK2 Transcripts in Patients with Chronic Myeloproliferative Neoplasias. Journal of Molecular Diagnostics. 11(1). 49–53. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yvona Brychtová Breakdown of academic impact, for papers by Mirosław Majewski Breakdown of academic impact, for papers by Iman Jilani Breakdown of academic impact, for papers by Kourong Miao Breakdown of academic impact, for papers by Kimberly Hayes Breakdown of academic impact, for papers by Carsten Schwäenen Breakdown of academic impact, for papers by Oscar Brück Breakdown of academic impact, for papers by Shelonitda Rose Breakdown of academic impact, for papers by Linda Wellik Breakdown of academic impact, for papers by Alicja Gruszka
Rankless by CCL
2026